Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Deal-happy Sanofi to buy cancer-drug developer By Tracy Staton Apr 15, 2009 9:31am In its second half-billion-dollar deal in a week, Sanofi-Aventis has agreed to buy the U.S. cancer drug specialist BiPar Sciences, aiming to build up its presence in biotech oncology meds. Report